Agente antitumoral que contiene un derivado de citidina para administración continua intravenosa

Agente antitumoral que contiene un derivado de citidina para administración continua intravenosa

Un agente antitumoral que contiene 1-(3-C-etinil-b-D-ribopentofuranosil)citosina o una sal de la misma para uso enel tratamiento del cáncer, que se ha de administrar a un paciente con cáncer por administración intravenosa continuaa una dosis de 1,30 a 8,56 mg/m2 en términos de 1-(3 -C-etinil-b-D-rib...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: MITA, AKIRA, KOIZUMI, KATSUHISA, KAZUNO, HIROMI
Format: Patent
Sprache:spa
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator MITA, AKIRA
KOIZUMI, KATSUHISA
KAZUNO, HIROMI
description Un agente antitumoral que contiene 1-(3-C-etinil-b-D-ribopentofuranosil)citosina o una sal de la misma para uso enel tratamiento del cáncer, que se ha de administrar a un paciente con cáncer por administración intravenosa continuaa una dosis de 1,30 a 8,56 mg/m2 en términos de 1-(3 -C-etinil-b-D-ribopentofuranosil)citosina por cada período deadministración de 2 a 336 horas. To provide a method for administering ECyd to a patient, which realizes a continuous therapy without expressing peripheral neurotoxicity caused by ECyd and which exhibits an excellent therapeutic effect with ensuring prolongation of the survival of the patient. The invention provides an antitumor agent containing ECyd or a salt thereof, which is administered to a cancer patient through continuous intravenous administration at a dose of 1.30 to 8.56 mg/m 2 as reduced to ECyd, for each administration period of 2 to 336 hours.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_ES2402954TT3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ES2402954TT3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_ES2402954TT33</originalsourceid><addsrcrecordid>eNqNjUsKwkAQRLNxIeod2gMIksSFS5GIe7MPxUwrDUnPOJ9czCN4MQf0AK6qeLyilhVOD9bEBE2S8uQCRnpmJuMKYGXKSpaDzLCuFDKSxIqCPAIIdhKVmAKMvF_6XWkGiRY2s7qIdbW4Y4y8-eWq2l66_nzdsXcDRw9TbtLQ3ep2Xx8Pbd83zT_OB7GjP4w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Agente antitumoral que contiene un derivado de citidina para administración continua intravenosa</title><source>esp@cenet</source><creator>MITA, AKIRA ; KOIZUMI, KATSUHISA ; KAZUNO, HIROMI</creator><creatorcontrib>MITA, AKIRA ; KOIZUMI, KATSUHISA ; KAZUNO, HIROMI</creatorcontrib><description>Un agente antitumoral que contiene 1-(3-C-etinil-b-D-ribopentofuranosil)citosina o una sal de la misma para uso enel tratamiento del cáncer, que se ha de administrar a un paciente con cáncer por administración intravenosa continuaa una dosis de 1,30 a 8,56 mg/m2 en términos de 1-(3 -C-etinil-b-D-ribopentofuranosil)citosina por cada período deadministración de 2 a 336 horas. To provide a method for administering ECyd to a patient, which realizes a continuous therapy without expressing peripheral neurotoxicity caused by ECyd and which exhibits an excellent therapeutic effect with ensuring prolongation of the survival of the patient. The invention provides an antitumor agent containing ECyd or a salt thereof, which is administered to a cancer patient through continuous intravenous administration at a dose of 1.30 to 8.56 mg/m 2 as reduced to ECyd, for each administration period of 2 to 336 hours.</description><language>spa</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2013</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20130510&amp;DB=EPODOC&amp;CC=ES&amp;NR=2402954T3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25569,76552</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20130510&amp;DB=EPODOC&amp;CC=ES&amp;NR=2402954T3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>MITA, AKIRA</creatorcontrib><creatorcontrib>KOIZUMI, KATSUHISA</creatorcontrib><creatorcontrib>KAZUNO, HIROMI</creatorcontrib><title>Agente antitumoral que contiene un derivado de citidina para administración continua intravenosa</title><description>Un agente antitumoral que contiene 1-(3-C-etinil-b-D-ribopentofuranosil)citosina o una sal de la misma para uso enel tratamiento del cáncer, que se ha de administrar a un paciente con cáncer por administración intravenosa continuaa una dosis de 1,30 a 8,56 mg/m2 en términos de 1-(3 -C-etinil-b-D-ribopentofuranosil)citosina por cada período deadministración de 2 a 336 horas. To provide a method for administering ECyd to a patient, which realizes a continuous therapy without expressing peripheral neurotoxicity caused by ECyd and which exhibits an excellent therapeutic effect with ensuring prolongation of the survival of the patient. The invention provides an antitumor agent containing ECyd or a salt thereof, which is administered to a cancer patient through continuous intravenous administration at a dose of 1.30 to 8.56 mg/m 2 as reduced to ECyd, for each administration period of 2 to 336 hours.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2013</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjUsKwkAQRLNxIeod2gMIksSFS5GIe7MPxUwrDUnPOJ9czCN4MQf0AK6qeLyilhVOD9bEBE2S8uQCRnpmJuMKYGXKSpaDzLCuFDKSxIqCPAIIdhKVmAKMvF_6XWkGiRY2s7qIdbW4Y4y8-eWq2l66_nzdsXcDRw9TbtLQ3ep2Xx8Pbd83zT_OB7GjP4w</recordid><startdate>20130510</startdate><enddate>20130510</enddate><creator>MITA, AKIRA</creator><creator>KOIZUMI, KATSUHISA</creator><creator>KAZUNO, HIROMI</creator><scope>EVB</scope></search><sort><creationdate>20130510</creationdate><title>Agente antitumoral que contiene un derivado de citidina para administración continua intravenosa</title><author>MITA, AKIRA ; KOIZUMI, KATSUHISA ; KAZUNO, HIROMI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_ES2402954TT33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>spa</language><creationdate>2013</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>MITA, AKIRA</creatorcontrib><creatorcontrib>KOIZUMI, KATSUHISA</creatorcontrib><creatorcontrib>KAZUNO, HIROMI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>MITA, AKIRA</au><au>KOIZUMI, KATSUHISA</au><au>KAZUNO, HIROMI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Agente antitumoral que contiene un derivado de citidina para administración continua intravenosa</title><date>2013-05-10</date><risdate>2013</risdate><abstract>Un agente antitumoral que contiene 1-(3-C-etinil-b-D-ribopentofuranosil)citosina o una sal de la misma para uso enel tratamiento del cáncer, que se ha de administrar a un paciente con cáncer por administración intravenosa continuaa una dosis de 1,30 a 8,56 mg/m2 en términos de 1-(3 -C-etinil-b-D-ribopentofuranosil)citosina por cada período deadministración de 2 a 336 horas. To provide a method for administering ECyd to a patient, which realizes a continuous therapy without expressing peripheral neurotoxicity caused by ECyd and which exhibits an excellent therapeutic effect with ensuring prolongation of the survival of the patient. The invention provides an antitumor agent containing ECyd or a salt thereof, which is administered to a cancer patient through continuous intravenous administration at a dose of 1.30 to 8.56 mg/m 2 as reduced to ECyd, for each administration period of 2 to 336 hours.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language spa
recordid cdi_epo_espacenet_ES2402954TT3
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title Agente antitumoral que contiene un derivado de citidina para administración continua intravenosa
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T03%3A59%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=MITA,%20AKIRA&rft.date=2013-05-10&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EES2402954TT3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true